DGX Quest Diagnostics Incorporated Common Stock
$240,56
السعر · أغسطس 21, 2026
البيانات الأساسية اعتبارًا من يوليو 23, 2026
نطاق 52 أسبوعًا
$171–$246
93% of range
تقييم المحللين
HOLD
23 analysts
السعر المستهدف
$246
+2% upside
P/E (TTM)
27.7
ROE
14.2%
هامش صافي الربح
9.0%
حول Quest Diagnostics Incorporated Common Stock نظرة عامة على الشركة من ويكيبيديا
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
اقرأ المزيد
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
As of 2020, the company had approximately 48,000 employees, and it generated more than $7.7 billion in revenue in 2019. The company offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders, COVID-19, and employment and court-ordered drug testing.
History
1960–1995
Originally founded as Metropolitan Pathology Laboratory, Inc. in 1967 by Paul A. Brown, MD, the clinical laboratory underwent a variety of name changes. In 1969, the company's name changed to MetPath, Inc. with headquarters in Teaneck, New Jersey. By 1982, MetPath was acquired by what was then known as Corning Glass Works and was subsequently renamed Corning Clinical Laboratories.
1996–2000
On December 31, 1996, Quest Diagnostics became an independent company as a spin-off from Corning. Kenneth W. Freeman was appointed as CEO during this transition. Over the next year, Quest acquired a clinical laboratory division of Branford, Connecticut–based Diagnostic Medical Laboratory, Inc. (DML). Two years later in 1999, Quest added SmithKline Beecham Clinical Laboratories to their subsidiaries; which includes a joint venture ownership with CompuNet Clinical Laboratory. The purchase of SmithKline Beecham also included the lab's medical sample transport airline (ICAO: LBQ, call sign: LABQUEST) originally founded in 1988.
In 1997, Quest and Banner Health formed a joint venture creating the Arizona based Sonora Quest laboratory, a business unit of Laboratory Sciences of Arizona. This entity represents the operations of Quest Diagnostics in the Arizona regional market.
2001–2015
From May 2004 to April 2012, Surya Mohapatra served as the company's President and CEO. In 2007 Quest acquired diagnostic testing equipment company AmeriPath. In response to Mohapatra's resignation after eight years with Quest, former Philips Healthcare CEO Stephen Rusckowski was appointed. Under Rusckowski, Quest Diagnostics teamed up with central New England's largest health care system, UMass Memorial Health Care, to purchase its clinical outreach laboratory.
2016–present
In 2016, Quest collaborated with Safeway to bring testing services to twelve of its stores in California, Maryland, Virginia, Texas and Colorado.
By the end of 2017, Quest, in partnership with Walmart, incorporated laboratory testing in about 15 of their locations in Texas and Florida.
In May 2018, the company announced it will become an in-network laboratory provider to UnitedHealthcare starting in 2019, providing access to 48 million plan members.
In September 2018, Quest moved its headquarters from Madison, where it was located since 2007, to Secaucus, New Jersey.
In November 2018, Quest launched QuestDirect, a consumer-initiated testing service that allows patients to order health and wellness lab testing from home.
In March 2020, the company launched a COVID-19 testing service. As of July 2020, Quest had performed more than 9.2 million COVID-19 molecular tests and 2.8 million serology tests.
In April 2024, Quest has added a new blood screening to their AD-Detect product line. This test will analyze the blood for a specific Alzheimer's protein, pTau-217.
In February 2025, Quest acquired select assets of Fresenius Medical Care's Spectra laboratories. Under a separate agreement, Quest now offers clinical testing and lab services related to dialysis and end-stage kidney disease.
Acquisitions
Partnerships
2005: Forms a strategic alliance with Ciphergen Biosystems to commercialize novel proteomic tests.
Controversies
Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical laboratory for manufacturing and distributing a faulty product. In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state's Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs.
In 2018, Quest Diagnostics was among a number of U.S.–based laboratories linked to inaccuracies of over 200 women's cervical smear tests for CervicalCheck, Ireland's national screening program. Audits of the testing performed by Quest (and another subcontractor, Clinical Pathology Laboratories, Inc. of Austin, Texas) showed a high rate of errors in analysis of samples which led to lawsuits and a government inquiry. Quest and the Irish government continue to settle the resulting lawsuits.
On June 3, 2019, Quest announced that American Medical Collection Agency (AMCA), a billing collections service provider, had informed Quest Diagnostics that an unauthorized user had access to AMCA’s system containing personal information AMCA received from various entities, including from Quest. AMCA provides billing collections services to Optum360, which in turn is a Quest contractor. AMCA later went bankrupt after the breach.
المصدر: ويكيبيديا (الإنجليزية), CC BY-SA 4.0 · عرض على ويكيبيديا ↗
DGX لقطة سريعة للسهم السعر، القيمة السوقية، مكرر الربحية (P/E)، ربحية السهم (EPS)، العائد على حقوق الملكية (ROE)، نسبة الدين إلى حقوق الملكية، نطاق 52 أسبوعًا
السعر
$240.56
القيمة السوقية
$26.70B
P/E (TTM)
27.7
ربح السهم (آخر 12 شهرًا)
$8.75
الإيرادات (آخر 12 شهرًا)
$11.04B
عائد التوزيعات
1.3%
ROE
14.2%
D/E الدين/حقوق الملكية
0.8
نطاق 52 أسبوعًا
$171 – $246
DGX مخطط سعر السهم OHLCV يومي مع مؤشرات فنية — تحريك وتكبير وتخصيص عرضك
Configure
أداء 10 سنوات اتجاهات الإيرادات وصافي الدخل والهوامش وربحية السهم
الإيرادات وصافي الدخل
$11.04B
2016-12-31
→
2025-12-31
ربح السهم
$8.75
2016-12-31
→
2025-12-31
التدفق النقدي الحر
$1.36B
2016-12-31
→
2025-12-31
الهوامش
9.0%
2016-12-31
→
2020-12-31
التقييم نسب مكرر الربحية (P/E)، مكرر المبيعات (P/S)، مكرر القيمة الدفترية (P/B)، EV/EBITDA — هل السهم مرتفع السعر أم رخيص؟
المقياس
اتجاه 5 سنوات
DGX
متوسط الأقران
P/E (TTM)
27.7
26.5
P/S (TTM) (السعر / المبيعات (آخر 12 شهرًا))
2.4
2.0
P/B (السعر / القيمة الدفترية)
3.7
4.9
EV / EBITDA
15.0
—
Price / FCF (السعر / التدفق النقدي الحر)
19.6
—
الربحية هامش الربح الإجمالي والتشغيلي والصافي؛ العائد على حقوق الملكية (ROE)، العائد على الأصول (ROA)، العائد على رأس المال المستثمر (ROIC)
المقياس
اتجاه 5 سنوات
DGX
متوسط الأقران
Operating Margin (هامش التشغيل)
14.1%
—
Net Profit Margin (هامش صافي الربح)
9.0%
4.0%
ROA (العائد على الأصول)
6.1%
5.0%
ROE
14.2%
15.2%
ROIC
9.2%
—
الصحة المالية الديون، السيولة، الملاءة المالية — قوة الميزانية العمومية
المقياس
اتجاه 5 سنوات
DGX
متوسط الأقران
Debt / Equity (الدين / حقوق الملكية)
0.8
—
Current Ratio (النسبة الحالية)
1.0
1.6
Quick Ratio (النسبة السريعة)
0.8
—
النمو نمو الإيرادات وربحية السهم وصافي الدخل: مقارنة بالعام السابق (YoY)، متوسط النمو السنوي المركب لـ 3 سنوات (3Y CAGR)، متوسط النمو السنوي المركب لـ 5 سنوات (5Y CAGR)
المقياس
اتجاه 5 سنوات
DGX
متوسط الأقران
Revenue YoY (الإيرادات مقارنة بالعام السابق)
11.8%
—
Revenue CAGR 3Y (معدل نمو الإيرادات السنوي المركب لـ 3 سنوات)
3.7%
—
Revenue CAGR 5Y (معدل نمو الإيرادات السنوي المركب لـ 5 سنوات)
3.2%
—
EPS YoY (ربحية السهم على أساس سنوي)
13.8%
—
Net Income YoY (صافي الدخل مقارنة بالعام السابق)
13.9%
—
كفاءة رأس المال معدل دوران الأصول، معدل دوران المخزون، معدل دوران المستحقات
المقياس
اتجاه 5 سنوات
DGX
متوسط الأقران
Payout Ratio (نسبة التوزيع)
35.6%
—
التوزيعات العائد، نسبة التوزيع، تاريخ توزيع الأرباح، معدل النمو السنوي المركب لمدة 5 سنوات
عائد الأرباح
1.3%
نسبة التوزيع
35.6%
5Y Div CAGR
—
| تاريخ الاستحقاق | المبلغ |
|---|---|
| 8 يوليو، 2026 | $0,8600 |
| 6 إبريل، 2026 | $0,8600 |
| 13 يناير، 2026 | $0,8000 |
| 3 أكتوبر، 2025 | $0,8000 |
| 7 يوليو، 2025 | $0,8000 |
| 7 إبريل، 2025 | $0,8000 |
| 14 يناير، 2025 | $0,7500 |
| 4 أكتوبر، 2024 | $0,7500 |
| 8 يوليو، 2024 | $0,7500 |
| 5 إبريل، 2024 | $0,7500 |
| 16 يناير، 2024 | $0,7100 |
| 5 أكتوبر، 2023 | $0,7100 |
| 10 يوليو، 2023 | $0,7100 |
| 6 إبريل، 2023 | $0,7100 |
| 17 يناير، 2023 | $0,6600 |
| 3 أكتوبر، 2022 | $0,6600 |
| 5 يوليو، 2022 | $0,6600 |
| 5 إبريل، 2022 | $0,6600 |
| 18 يناير، 2022 | $0,6200 |
| 4 أكتوبر، 2021 | $0,6200 |
DGX توافق الآراء التحليلي آراء المحللين الصعودية والهبوطية، السعر المستهدف لمدة 12 شهرًا، الصعود
شراء
23 محللين
- شراء قوي 6 26,1%
- شراء 7 30,4%
- احتفاظ 10 43,5%
- بيع 0 0,0%
- بيع قوي 0 0,0%
السعر المستهدف لمدة 12 شهرًا
15 محللين · 2026-08-16
الوسيط
$250.00
الآن
$240.56
منخفض
$204.00
مرتفع
$265.00
السعر المستهدف الوسيط
$250.00
+3,9%
السعر المستهدف المتوسط
$245.87
+2,2%
سجل الأرباح ربحية السهم الفعلية مقابل التقديرات، نسبة المفاجأة %، معدل التجاوز، تاريخ الأرباح التالي
متوسط المفاجأة
0.09%
| الفترة | EPS Actual | EPS المتوقع | المفاجأة |
|---|---|---|---|
| 30 يونيو، 2026 | $3.12 | $2.85 | 0.27% |
| 31 مارس، 2026 | $2.50 | $2.37 | 0.13% |
| 31 ديسمبر، 2025 | $2.42 | $2.38 | 0.04% |
| 30 سبتمبر، 2025 | $2.60 | $2.53 | 0.07% |
| 30 يونيو، 2025 | $2.62 | $2.60 | 0.02% |
| 31 مارس، 2025 | $2.21 | $2.17 | 0.04% |
مقارنة الأقران (الصناعة الفرعية GICS) المقاييس الرئيسية مقابل أقران القطاع
| الرمز | القيمة السوقية | P/E | الإيرادات سنويًا | هامش الربح الصافي | ROE | هامش الربح الإجمالي |
|---|---|---|---|---|---|---|
| DGX | $19.09B | 19.8 | 11.8% | 9.0% | 14.2% | — |
| CVS | $100.87B | 57.1 | 7.8% | 0.44% | 2.4% | — |
| CI | $72.51B | 12.4 | 11.2% | 2.2% | 14.4% | — |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| GH | $13.34B | -30.8 | 32.9% | -42.4% | 205.7% | — |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| BTSG | $7.20B | 43.0 | 28.2% | 1.5% | 10.8% | 11.8% |
| DVA | $7.79B | 11.5 | 6.5% | 5.5% | -281.8% | — |
| HIMS | — | 63.7 | 59.0% | 5.5% | 23.3% | 73.8% |
| HNGE | $0 | -6.0 | 50.6% | -89.9% | -299.8% | 79.7% |
| CHE | — | 23.3 | 4.1% | 10.5% | 24.4% | — |
الأساسيات الكاملة جميع المقاييس حسب السنة — قائمة الدخل، الميزانية العمومية، التدفق النقدي
قائمة الدخل 17
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Cost of Revenue | $7.37B | $6.63B | $6.20B | $6.45B | $6.58B | $5.80B | $5.04B | $4.93B | $4.72B | $4.62B | $4.66B | $4.64B | |
| Gross Profit | · | · | · | · | · | $3.63B | $2.69B | $2.60B | $2.68B | $2.90B | $2.84B | $2.80B | |
| SG&A Expense | $1.97B | $1.77B | $1.64B | $1.87B | $1.73B | $1.55B | $1.46B | $1.42B | $1.44B | $1.38B | $1.68B | $1.73B | |
| Operating Expenses | $9.48B | $8.53B | $7.99B | $8.46B | $8.41B | $7.47B | $6.50B | $6.43B | $6.24B | $5.94B | $6.09B | $6.45B | |
| Operating Income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B | $1.23B | $1.10B | $1.17B | $1.28B | $1.40B | $983M | |
| Interest Expense | · | · | $163M | $148M | $152M | $166M | $180M | $169M | $153M | $144M | $154M | $167M | |
| Interest Income | $13M | $25M | $11M | $10M | $1M | $3M | $5M | $2M | $2M | $1M | $1M | $3M | |
| Other Non-op | $26M | $30M | $20M | $-55M | $369M | $76M | $20M | $-8M | $16M | $-48M | $-143M | $4M | |
| Pretax Income | $1.32B | $1.18B | $1.13B | $1.24B | $2.60B | $1.88B | $1.08B | $926M | $1.03B | $1.09B | $1.10B | $823M | |
| Income Tax | $314M | $273M | $248M | $264M | $597M | $460M | $247M | $182M | $241M | $429M | $373M | $262M | |
| Net Income | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| EPS (Basic) | $8.87 | $7.78 | $7.59 | $8.10 | $15.85 | $10.62 | $6.36 | $5.39 | $5.63 | $4.58 | $4.92 | $3.83 | |
| EPS (Diluted) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 | |
| Shares (Basic) | 111,000,000 | 111,000,000 | 112,000,000 | 116,000,000 | 125,000,000 | 134,000,000 | 134,000,000 | 136,000,000 | 137,000,000 | 140,000,000 | 144,000,000 | 145,000,000 | |
| Shares (Diluted) | 113,000,000 | 113,000,000 | 113,000,000 | 118,000,000 | 128,000,000 | 136,000,000 | 136,000,000 | 139,000,000 | 140,000,000 | 142,000,000 | 145,000,000 | 145,000,000 | |
| EBITDA | $2.13B | $1.84B | $1.70B | $1.86B | $2.79B | $2.33B | $1.56B | $1.41B | $1.44B | $1.53B | $1.70B | $1.30B |
الميزانية العمومية 27
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $420M | $549M | $686M | $315M | $872M | $1.16B | $1.19B | $135M | $137M | $359M | $133M | $192M | |
| Receivables | $1.41B | $1.30B | $1.21B | $1.20B | $1.44B | $1.52B | $1.06B | $1.01B | $924M | $926M | $901M | $932M | |
| Inventory | $189M | $188M | $190M | $192M | $208M | $223M | $123M | $99M | $95M | $82M | $84M | $110M | |
| Prepaid Expense | $361M | $351M | $286M | $196M | $223M | $157M | $112M | $144M | $150M | $155M | $207M | $186M | |
| Current Assets | $2.38B | $2.39B | $2.37B | $1.90B | $2.74B | $3.06B | $2.49B | $1.39B | $1.31B | $1.53B | $1.50B | $1.60B | |
| PP&E (Net) | $2.20B | $2.11B | $1.82B | $1.77B | $1.71B | $1.63B | $1.45B | $1.29B | $1.15B | $1.03B | $925M | $933M | |
| PP&E (Gross) | $6.18B | $5.77B | $5.23B | $5.10B | $4.79B | $4.62B | $4.23B | $3.97B | $3.67B | $3.43B | $3.23B | $3.13B | |
| Accum. Depreciation | $3.97B | $3.66B | $3.42B | $3.34B | $3.09B | $2.99B | $2.78B | $2.68B | $2.53B | $2.40B | $2.31B | $2.19B | |
| Goodwill | $8.95B | $8.86B | $7.73B | $7.22B | $7.09B | $6.87B | $6.62B | $6.56B | $6.33B | $6.00B | $5.91B | $6.03B | |
| Intangibles | $1.64B | $1.76B | $1.17B | $1.09B | $1.17B | $1.17B | $1.12B | $1.21B | $1.12B | $949M | $984M | $1.07B | |
| Other Non-current Assets | $270M | $255M | $198M | $144M | $163M | $176M | $160M | $119M | $136M | $148M | $174M | $172M | |
| Total Assets | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Accounts Payable | $1.60B | $1.39B | $1.36B | $1.40B | $1.60B | $1.63B | $1.04B | $1.02B | $1.02B | $975M | $1.01B | $1.19B | |
| Accrued Liabilities | $338M | $306M | $287M | $392M | $460M | $356M | $223M | $274M | $246M | $254M | $257M | $277M | |
| Current Liabilities | $2.28B | $2.17B | $1.81B | $1.55B | $1.75B | $1.78B | $1.99B | $1.49B | $1.06B | $981M | $1.17B | $1.71B | |
| Capital Leases | $537M | $535M | $503M | $489M | $494M | $499M | $413M | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $264M | $243M | $170M | $191M | $157M | $204M | |
| Other Non-current Liabilities | $957M | $938M | $876M | $812M | $792M | $847M | $711M | $745M | $663M | $654M | $514M | $594M | |
| Long-term Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.74B | |
| Total Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.76B | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Retained Earnings | $9.99B | $9.36B | $8.82B | $8.29B | $7.65B | $9.30B | $8.17B | $7.60B | $7.14B | $6.61B | $6.20B | $5.72B | |
| Treasury Stock | $5.18B | $4.86B | $4.83B | $4.67B | $3.45B | $5.37B | $5.22B | $5.00B | $4.78B | $4.46B | $3.96B | $3.81B | |
| AOCI | $-27M | $-88M | $-14M | $-21M | $-14M | $-21M | $-39M | $-59M | $-48M | $-72M | $-38M | $-27M | |
| Stockholders' Equity | $7.17B | $6.78B | $6.31B | $5.89B | $6.44B | $6.76B | $5.64B | $5.22B | $4.92B | $4.63B | $4.68B | $4.30B | |
| Liabilities + Equity | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 119,000,000 | 133,000,000 | 133,000,000 | 135,000,000 | 135,000,000 | 137,000,000 | 143,000,000 | 144,000,000 |
التدفق النقدي 17
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $570M | $493M | $439M | $437M | $408M | $361M | $329M | $309M | $270M | $249M | $304M | $314M | |
| Stock-based Comp | $88M | $88M | $77M | $77M | $79M | $97M | $56M | $61M | $79M | $69M | $52M | $51M | |
| Deferred Tax | $105M | $13M | $-49M | $1M | $-57M | $85M | $15M | $73M | $9M | $37M | $112M | $23M | |
| Amort. of Intangibles | $154M | $127M | $108M | $120M | $103M | $103M | $96M | $90M | $74M | $72M | $81M | $94M | |
| Restructuring | · | · | · | $55M | $13M | $14M | $-3M | $49M | $30M | $11M | $39M | $43M | |
| Other Non-cash | $131M | $-131M | $-49M | $257M | $-192M | $31M | $-15M | $21M | $45M | $69M | $-367M | $-6M | |
| Operating Cash Flow | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B | $2.00B | $1.24B | $1.20B | $1.18B | $1.12B | $821M | $944M | |
| CapEx | $527M | $425M | $408M | $404M | $403M | $418M | $400M | $383M | $252M | $293M | $263M | $308M | |
| Investing Cash Flow | $-631M | $-2.55B | $-1.06B | $-543M | $21M | $-772M | $-411M | $-801M | $-830M | $-127M | $-362M | $-1.02B | |
| Stock Repurchased | $450M | $151M | $275M | $1.41B | $2.20B | $325M | $353M | $322M | $465M | $590M | $224M | $132M | |
| Net Stock Activity | $-450M | $-151M | $-275M | $-1.41B | $-2.20B | $-325M | $-353M | $-322M | $-465M | $-590M | $-224M | $-132M | |
| Dividends Paid | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M | |
| Financing Cash Flow | $-1.39B | $1.08B | $160M | $-1.73B | $-2.54B | $-1.27B | $225M | $-401M | $-592M | $-738M | $-518M | $86M | |
| Net Change in Cash | $-129M | $-137M | $371M | $-557M | $-286M | · | · | · | $-222M | $226M | $-59M | $5M | |
| Taxes Paid | $169M | $256M | $317M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $1.36B | $909M | $864M | $1.31B | $1.83B | $1.59B | $843M | $817M | $923M | $776M | $547M | $630M | |
| Levered FCF | · | · | $737M | $1.20B | $1.71B | $1.46B | $704M | $681M | $806M | $689M | · | · |
الربحية 8
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 38.5% | 34.8% | 34.6% | 38.8% | 38.6% | 37.9% | 37.6% | |
| Operating Margin | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% | 20.9% | 15.9% | 14.6% | 15.1% | 17.0% | 18.7% | 13.2% | |
| Net Margin | 9.0% | 8.8% | 9.2% | 9.6% | 18.5% | 15.2% | 11.1% | 9.8% | 10.0% | 8.6% | 9.5% | 7.5% | |
| Pretax Margin | 11.9% | 11.9% | 12.2% | 12.5% | 24.1% | 20.0% | 13.9% | 12.3% | 13.4% | 14.4% | 14.7% | · | |
| EBITDA Margin | 19.3% | 18.6% | 18.4% | 18.9% | 25.9% | 24.7% | 20.2% | 18.7% | 18.6% | 20.3% | 22.7% | 17.4% | |
| ROA | 6.1% | 5.8% | 6.4% | 7.1% | 14.4% | 10.7% | 7.2% | 6.8% | 7.5% | 6.4% | 7.1% | 5.9% | |
| ROE | 14.2% | 13.3% | 14.0% | 15.3% | 30.2% | 23.1% | 15.8% | 14.5% | 16.2% | 13.9% | 15.8% | 13.5% | |
| ROIC | 9.2% | 8.0% | 8.9% | 11.4% | 17.5% | 13.8% | 9.1% | 9.7% | 10.2% | 9.2% | 11.1% | · |
السيولة والملاءة 5
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 | 1.7 | 1.3 | 0.9 | 1.2 | 1.6 | 1.3 | 0.9 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 | 1.5 | 1.1 | 0.8 | 1.0 | 1.3 | 0.9 | 0.7 | |
| Debt / Equity | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 | 0.6 | 0.8 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | |
| LT Debt / Equity | 0.7 | 0.8 | 0.7 | 0.7 | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 | 0.8 | 0.7 | 0.8 | |
| Interest Coverage | · | · | 7.7 | 9.6 | 15.7 | 11.9 | 6.8 | 6.5 | 7.6 | 8.9 | · | · |
الكفاءة 3
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.8 | 0.8 | |
| Inventory Turnover | 39.1 | 35.1 | 32.5 | 32.2 | 30.5 | 33.5 | 45.4 | 50.8 | 53.3 | 55.6 | 48.0 | 46.1 | |
| Receivables Turnover | 8.1 | 7.9 | 7.7 | 7.5 | 7.3 | 7.3 | 7.4 | 7.8 | 8.3 | 8.2 | 8.2 | 8.3 |
معدلات النمو 10
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.8% | 6.7% | -6.4% | -8.4% | 14.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 3.7% | -2.9% | -0.66% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 3.2% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 13.8% | 2.7% | -6.0% | -48.8% | 48.5% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 3.2% | -20.9% | -10.6% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -3.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 13.9% | 2.0% | -9.7% | -52.6% | 39.4% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 1.6% | -24.1% | -15.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -7.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 3.5% | · | · | · | · | · | · | · | · | · | · | · |
التقييم (آخر 12 شهرًا) 16
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Net Income TTM | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| Market Cap | $19.09B | $16.75B | $15.30B | $17.36B | $20.59B | $15.85B | $14.20B | $11.24B | $13.30B | $12.59B | $10.17B | $9.66B | |
| Enterprise Value | $24.34B | $22.41B | $19.33B | $21.03B | $23.73B | $18.71B | $17.78B | $15.00B | $16.94B | $15.97B | $13.69B | $13.23B | |
| P/E | 19.8 | 19.6 | 18.4 | 19.6 | 11.1 | 11.4 | 17.0 | 15.7 | 17.9 | 20.4 | 14.6 | 17.6 | |
| P/S | 1.7 | 1.7 | 1.7 | 1.8 | 1.9 | 1.7 | 1.8 | 1.5 | 1.8 | 1.7 | 1.4 | 1.3 | |
| P/B | 2.7 | 2.5 | 2.4 | 2.9 | 3.2 | 2.3 | 2.5 | 2.2 | 2.7 | 2.7 | 2.2 | 2.2 | |
| P / Cash Flow | 10.1 | 12.6 | 12.0 | 10.1 | 9.2 | 7.9 | 11.4 | 9.4 | 11.3 | 11.8 | 12.6 | 10.3 | |
| P / FCF | 14.0 | 18.4 | 17.7 | 13.2 | 11.3 | 10.0 | 16.8 | 13.8 | 14.4 | 16.2 | 18.6 | 15.3 | |
| EV / EBITDA | 11.4 | 12.2 | 11.4 | 11.3 | 8.5 | 8.0 | 11.4 | 10.6 | 11.8 | 10.5 | 8.0 | 10.2 | |
| EV / FCF | 17.9 | 24.7 | 22.4 | 16.0 | 13.0 | 11.8 | 21.1 | 18.4 | 18.4 | 20.6 | 25.0 | 21.0 | |
| EV / Revenue | 2.2 | 2.3 | 2.1 | 2.1 | 2.2 | 2.0 | 2.3 | 2.0 | 2.3 | 2.2 | 1.8 | 1.8 | |
| Dividend Yield | 1.8% | 2.0% | 2.1% | 1.8% | 1.5% | 1.9% | 2.0% | 2.4% | 1.9% | 1.8% | 2.1% | 1.9% | |
| Earnings Yield | 5.0% | 5.1% | 5.4% | 5.1% | 9.0% | 8.8% | 5.9% | 6.3% | 5.6% | 4.9% | 6.9% | 5.7% | |
| Payout Ratio | 35.6% | 38.0% | 36.8% | 32.2% | 15.5% | 20.8% | 33.3% | 36.1% | 32.0% | 34.6% | 29.9% | 33.6% | |
| Annual Payout | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M |
قائمة الدخل 16
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.04B | $2.90B | $2.81B | $2.82B | $2.76B | $2.65B | $2.62B | $2.49B | $2.40B | $2.37B | $2.29B | $2.29B | $2.34B | $2.33B | $2.33B | $2.49B | |
| Cost of Revenue | $2.02B | $1.95B | $1.90B | $1.87B | $1.82B | $1.79B | $1.76B | $1.68B | $1.59B | $1.59B | $1.55B | $1.54B | $1.55B | $1.56B | $1.57B | $1.62B | |
| SG&A Expense | $529M | $504M | $504M | $501M | $486M | $476M | $466M | $448M | $416M | $440M | $407M | $380M | $416M | $439M | $563M | $464M | |
| Operating Expenses | $2.58B | $2.50B | $2.42B | $2.43B | $2.32B | $2.31B | $2.26B | $2.16B | $2.04B | $2.07B | $2.02B | $1.95B | $1.99B | $2.03B | $2.20B | $2.09B | |
| Operating Income | $459M | $399M | $386M | $386M | $438M | $346M | $361M | $330M | $355M | $300M | $267M | $342M | $348M | $305M | $135M | $392M | |
| Interest Expense | · | · | · | · | · | · | · | · | $47M | $49M | · | $41M | $39M | $37M | · | $37M | |
| Interest Income | $5M | $2M | $3M | $3M | $2M | $5M | $7M | $9M | $3M | $6M | $6M | $1M | $2M | $2M | $4M | $4M | |
| Other Non-op | $16M | $-2M | $8M | $8M | $13M | $-3M | $3M | $15M | $3M | $9M | $10M | $-3M | $6M | $7M | $6M | $-8M | |
| Pretax Income | $412M | $334M | $330M | $328M | $384M | $276M | $299M | $296M | $314M | $266M | $237M | $299M | $317M | $277M | $109M | $351M | |
| Income Tax | $88M | $74M | $81M | $77M | $97M | $59M | $68M | $65M | $74M | $66M | $40M | $68M | $75M | $65M | $-4M | $81M | |
| Net Income | $320M | $252M | $245M | $245M | $282M | $220M | $222M | $226M | $229M | $194M | $192M | $225M | $235M | $202M | $101M | $256M | |
| EPS (Basic) | $2.88 | $2.27 | $2.21 | $2.18 | $2.51 | $1.97 | $1.98 | $2.01 | $2.05 | $1.74 | $1.72 | $1.99 | $2.08 | $1.80 | $0.93 | $2.20 | |
| EPS (Diluted) | $2.84 | $2.24 | $2.18 | $2.16 | $2.47 | $1.94 | $1.95 | $1.99 | $2.03 | $1.72 | $1.70 | $1.96 | $2.05 | $1.78 | $0.92 | $2.17 | |
| Shares (Basic) | 111,000,000 | 110,000,000 | -224,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | -223,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | -224,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | -236,000,000 | 116,000,000 | |
| Shares (Diluted) | 112,000,000 | 112,000,000 | -226,000,000 | 113,000,000 | 113,000,000 | 113,000,000 | -224,000,000 | 113,000,000 | 112,000,000 | 112,000,000 | -228,000,000 | 114,000,000 | 114,000,000 | 113,000,000 | -240,000,000 | 118,000,000 | |
| EBITDA | $605M | $546M | · | $528M | $581M | $486M | · | $455M | $472M | $416M | · | $453M | $460M | $412M | · | $500M |
الميزانية العمومية 26
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $626M | $393M | $420M | $432M | $319M | $188M | $549M | $764M | $271M | $474M | · | $143M | $126M | $175M | · | $700M | |
| Receivables | $1.67B | $1.59B | $1.41B | $1.46B | $1.42B | $1.40B | $1.30B | $1.38B | $1.32B | $1.32B | · | $1.28B | $1.24B | $1.25B | · | $1.28B | |
| Inventory | $233M | $225M | $189M | $186M | $187M | $189M | $188M | $184M | $182M | $181M | · | $184M | $184M | $190M | · | $183M | |
| Prepaid Expense | $319M | $361M | $361M | $333M | $273M | $294M | $351M | $299M | $245M | $251M | · | $207M | $188M | $195M | · | $171M | |
| Current Assets | $2.84B | $2.57B | $2.38B | $2.41B | $2.20B | $2.08B | $2.39B | $2.62B | $2.02B | $2.23B | · | $1.81B | $1.73B | $1.81B | · | $2.33B | |
| PP&E (Net) | $2.22B | $2.19B | $2.20B | $2.15B | $2.12B | $2.10B | $2.11B | $2.09B | $1.83B | $1.81B | · | $1.83B | $1.81B | $1.79B | · | $1.71B | |
| PP&E (Gross) | · | · | $6.18B | · | · | · | $5.77B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $3.97B | · | · | · | $3.66B | · | · | · | · | · | · | · | · | · | |
| Goodwill | $9.11B | $9.12B | $8.95B | $8.90B | $8.88B | $8.85B | $8.86B | $8.61B | $7.88B | $7.83B | $7.73B | $7.73B | $7.73B | $7.24B | $7.22B | $7.19B | |
| Intangibles | $1.67B | $1.72B | $1.64B | $1.66B | $1.71B | $1.73B | $1.76B | $1.72B | $1.20B | $1.19B | · | $1.22B | $1.25B | $1.08B | · | $1.11B | |
| Other Non-current Assets | $277M | $256M | $270M | $296M | $271M | $260M | $255M | $272M | $216M | $182M | · | $149M | $152M | $150M | · | $132M | |
| Total Assets | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Accounts Payable | $1.60B | $1.50B | $1.60B | $1.46B | $1.35B | $1.27B | $1.39B | $1.31B | $1.25B | $1.24B | · | $1.16B | $1.20B | $1.20B | · | $1.45B | |
| Accrued Liabilities | · | · | $338M | · | · | · | $306M | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $1.79B | $2.18B | $2.28B | $2.13B | $2.02B | $1.44B | $2.17B | $2.09B | $2.01B | $2.30B | · | $1.62B | $1.88B | $1.35B | · | $1.60B | |
| Capital Leases | $561M | $574M | $537M | $534M | $540M | $538M | $535M | $543M | $507M | $489M | · | $505M | $508M | $490M | · | $505M | |
| Other Non-current Liabilities | $1.06B | $1.02B | $957M | $982M | $890M | $917M | $938M | $891M | $811M | $817M | · | $874M | $901M | $809M | · | $787M | |
| Long-term Debt | $5.64B | · | $5.67B | · | · | · | $6.22B | $6.25B | · | · | · | · | · | · | · | · | |
| Total Debt | $5.64B | $503M | · | $504M | $504M | $1M | · | $6.25B | $606M | $906M | · | $304M | $518M | $2M | · | $2M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $10.37B | $10.15B | $9.99B | $9.84B | $9.68B | $9.49B | $9.36B | $9.22B | $9.08B | $8.94B | · | $8.71B | $8.57B | $8.41B | · | $8.26B | |
| Treasury Stock | $5.17B | $5.09B | $5.18B | $4.90B | $4.77B | $4.79B | $4.86B | $4.73B | $4.76B | $4.78B | · | $4.57B | $4.59B | $4.61B | · | $4.27B | |
| AOCI | $-62M | $-43M | $-27M | $-40M | $-16M | $-83M | $-88M | $-15M | $-19M | $-16M | · | $-20M | $-16M | $-18M | · | $-31M | |
| Stockholders' Equity | $7.52B | $7.37B | $7.17B | $7.26B | $7.23B | $6.93B | $6.78B | $6.81B | $6.62B | $6.43B | · | $6.42B | $6.25B | $6.05B | · | $6.24B | |
| Liabilities + Equity | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 110,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 114,000,000 |
التدفق النقدي 16
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $146M | $147M | $145M | $142M | $143M | $140M | $135M | $125M | $117M | $116M | $109M | $111M | $112M | $107M | $116M | $108M | |
| Stock-based Comp | $23M | $20M | $25M | $20M | $21M | $22M | $27M | $19M | $20M | $22M | $19M | $18M | $16M | $24M | $22M | $18M | |
| Deferred Tax | $-2M | $48M | $-13M | $110M | $1M | $7M | $34M | $15M | $-18M | $-18M | $-10M | $-23M | $-12M | $-4M | $-44M | $65M | |
| Amort. of Intangibles | $38M | $37M | $37M | $39M | $39M | $39M | $37M | $32M | $29M | $29M | $27M | $27M | $28M | $26M | $39M | $27M | |
| Restructuring | · | · | · | $6M | $1M | · | · | $7M | $8M | · | · | $1M | $1M | · | · | · | |
| Other Non-cash | · | $-189M | · | · | · | $-75M | · | · | · | $-160M | · | · | · | $-235M | · | · | |
| Operating Cash Flow | $597M | $278M | $465M | $563M | $544M | $314M | $464M | $356M | $360M | $154M | $527M | $207M | $444M | $94M | $334M | $502M | |
| CapEx | $138M | $114M | $158M | $144M | $108M | $117M | $123M | $106M | $92M | $104M | $72M | $105M | $104M | $127M | $147M | $118M | |
| Investing Cash Flow | $-134M | $-152M | $-191M | $-201M | $-124M | $-115M | $-502M | $-1.63B | $-200M | $-213M | $-114M | $-107M | $-682M | $-158M | $-174M | $-118M | |
| Stock Repurchased | · | · | $300M | $150M | · | · | $151M | · | · | · | $275M | $0 | $0 | $0 | $461M | $374M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Dividends Paid | $96M | $88M | $90M | $89M | $90M | $84M | $84M | $84M | $84M | $79M | $80M | $80M | $80M | $74M | $75M | $78M | |
| Financing Cash Flow | $-229M | $-152M | $-287M | $-247M | $-293M | $-561M | $-170M | $1.77B | $-363M | $-153M | $130M | $-83M | $189M | $-76M | $-545M | $-474M | |
| Net Change in Cash | $233M | $-27M | $-12M | $113M | $131M | $-361M | $-215M | $493M | $-203M | $-212M | $543M | $17M | $-49M | $-140M | $-385M | $-90M | |
| Free Cash Flow | · | $164M | · | · | · | $197M | · | · | · | $50M | · | · | · | $-33M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $13M | · | · | · | $-61M | · | · |
الربحية 7
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.1% | 13.8% | · | 13.7% | 15.9% | 13.1% | · | 13.3% | 14.8% | 12.7% | · | 14.9% | 14.9% | 13.1% | · | 15.8% | |
| Net Margin | 10.5% | 8.7% | · | 8.7% | 10.2% | 8.3% | · | 9.1% | 9.6% | 8.2% | · | 9.8% | 10.1% | 8.7% | · | 10.3% | |
| Pretax Margin | 13.5% | 11.5% | · | 11.7% | 13.9% | 10.4% | · | 11.9% | 13.1% | 11.2% | · | 13.0% | 13.6% | 11.9% | · | 14.1% | |
| EBITDA Margin | 19.9% | 18.9% | · | 18.8% | 21.0% | 18.3% | · | 18.3% | 19.7% | 17.6% | · | 19.7% | 19.7% | 17.7% | · | 20.1% | |
| ROA | 1.9% | 1.6% | · | 1.5% | 1.9% | 1.5% | · | 1.5% | 1.7% | 1.5% | · | 1.7% | 1.8% | 1.5% | · | 1.9% | |
| ROE | 4.3% | 3.5% | · | 3.5% | 4.1% | 3.3% | · | 3.4% | 3.6% | 3.1% | · | 3.5% | 3.7% | 3.2% | · | 4.0% | |
| ROIC | 2.7% | 4.0% | · | 3.8% | 4.2% | 3.9% | · | 2.0% | 3.8% | 3.1% | · | 3.9% | 3.9% | 3.9% | · | 4.8% |
السيولة والملاءة 5
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.2 | · | 1.1 | 1.1 | 1.4 | · | 1.3 | 1.0 | 1.0 | · | 1.1 | 0.9 | 1.3 | · | 1.5 | |
| Quick Ratio | 1.3 | 0.9 | · | 0.9 | 0.9 | 1.1 | · | 1.0 | 0.8 | 0.8 | · | 0.9 | 0.7 | 1.1 | · | 1.2 | |
| Debt / Equity | 0.8 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.9 | 0.1 | 0.1 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | |
| LT Debt / Equity | 0.7 | · | · | · | · | · | · | 0.8 | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 7.6 | 6.1 | · | 8.3 | 8.9 | 8.2 | · | 10.6 |
الكفاءة 3
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 9.6 | 9.4 | · | 10.1 | 9.9 | 9.7 | · | 9.1 | 8.7 | 8.6 | · | 8.4 | 8.3 | 8.1 | · | 8.3 | |
| Receivables Turnover | 2.0 | 1.9 | · | 2.0 | 2.0 | 1.9 | · | 1.9 | 1.9 | 1.8 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
التقييم (آخر 12 شهرًا) 14
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.52B | $11.12B | · | $10.72B | $10.30B | $9.90B | · | $9.55B | $9.40B | $9.33B | · | $9.45B | $9.61B | $9.88B | · | $10.32B | |
| Net Income TTM | $1.10B | $999M | · | $973M | $957M | $869M | · | $874M | $883M | $856M | · | $918M | $927M | $1.05B | · | $1.35B | |
| Market Cap | $23.31B | $21.75B | · | $21.15B | $20.12B | $18.95B | · | $17.39B | $15.19B | $14.78B | · | $13.65B | $15.74B | $15.85B | · | $13.99B | |
| Enterprise Value | $28.33B | $21.86B | · | $21.23B | $20.30B | $18.76B | · | $22.88B | $15.53B | $15.21B | · | $13.81B | $16.13B | $15.67B | · | $13.29B | |
| P/E | 21.8 | 22.2 | · | 22.3 | 21.3 | 22.0 | · | 20.2 | 17.6 | 17.7 | · | 15.3 | 17.7 | 16.0 | · | 11.1 | |
| P/S | 2.0 | 2.0 | · | 2.0 | 2.0 | 1.9 | · | 1.8 | 1.6 | 1.6 | · | 1.4 | 1.6 | 1.6 | · | 1.4 | |
| P/B | 3.1 | 3.0 | · | 2.9 | 2.8 | 2.7 | · | 2.6 | 2.3 | 2.3 | · | 2.1 | 2.5 | 2.6 | · | 2.2 | |
| P / Cash Flow | · | 78.3 | · | · | · | 60.4 | · | · | · | 95.9 | · | · | · | 168.6 | · | · | |
| P / FCF | · | 132.6 | · | · | · | 96.2 | · | · | · | 295.5 | · | · | · | -480.2 | · | · | |
| EV / EBITDA | 46.8 | 40.0 | · | 40.2 | 34.9 | 38.6 | · | 50.3 | 32.9 | 36.6 | · | 30.5 | 35.1 | 38.0 | · | 26.6 | |
| EV / FCF | · | 133.3 | · | · | · | 95.2 | · | · | · | 304.1 | · | · | · | -474.9 | · | · | |
| EV / Revenue | 2.5 | 2.0 | · | 2.0 | 2.0 | 1.9 | · | 2.4 | 1.7 | 1.6 | · | 1.5 | 1.7 | 1.6 | · | 1.3 | |
| Earnings Yield | 4.6% | 4.5% | · | 4.5% | 4.7% | 4.5% | · | 5.0% | 5.7% | 5.6% | · | 6.5% | 5.7% | 6.2% | · | 9.0% | |
| Payout Ratio | · | 34.9% | · | · | · | 38.2% | · | · | · | 40.7% | · | · | · | 36.6% | · | · |
القوائم المالية قائمة الدخل، الميزانية العمومية، التدفقات النقدية — سنويًا، آخر 5 سنوات
قائمة الدخل
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الإيرادات | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B |
| هامش الربح التشغيلي % | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% |
| صافي الدخل | $992M | $871M | $854M | $946M | $2.00B |
| EPS المخفف | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
الميزانية العمومية
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الدين / حقوق الملكية | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 |
| النسبة الحالية | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 |
| النسبة السريعة | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 |
التدفق النقدي
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| التدفق النقدي الحر | $1.36B | $909M | $864M | $1.31B | $1.83B |
آخر الأخبار أحدث العناوين التي تذكر هذه الشركة
مقاييسي قائمة المراقبة الشخصية الخاصة بك — صفوف مختارة من الأساسيات الكاملة
📊
اختر المقاييس التي تهمك — انقر فوق علامة ➕ بجوار أي صف في الأساسيات الكاملة أعلاه.
يتم حفظ اختيارك ويتبعك عبر جميع الأسهم.
الملاك المؤسسيون (13F) 1176 مقدمي إقرار · $12.9B إجمالي · حتى تاريخ 30 يونيو، 2026
المؤسسات التي تبلغ عن حيازتها لهذا السهم في نموذج SEC 13F ربع السنوي الخاص بها. المراكز الطويلة فقط؛ قد يظهر مقدم واحد مرتين لأرجل خيارات منفصلة. الأرجل الكبيرة المتعاكسة من خيارات البيع/الشراء تعكس عادةً صناعة السوق أو المخزون المتحوط، وليس القناعة الاتجاهية.
النشاط المؤسسي — Q2 2026 مقابل الربع السابق
| مراكز جديدة | المراكز الخارجة | زيادة | انخفض | صافي التغير في الأسهم |
|---|---|---|---|---|
| 115 (-25 مقابل الربع السابق) | 64 (-17 مقابل الربع السابق) | 415 (+69 مقابل الربع السابق) | 333 (-20 مقابل الربع السابق) | +7.5M |
مقارنة بـ Q1 2026. المواعيد النهائية لتقديم إقرارات نموذج 13F لهيئة الأوراق المالية والبورصات (SEC) هي في غضون 45 يومًا من نهاية الربع بالإضافة إلى فترة سماح قصيرة للمقدمين المتأخرين — يتم تخطي الأرباع التي لا تزال ضمن هذه النافذة لصالح أحدث زوج تم الإبلاغ عنه بالكامل.
| مؤسسة | القيمة | الأسهم | % من 13F المتتبعة | النوع |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $1533117858 | 7233394 | 11,92% | الأسهم |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1299474988 | 6131045 | 10,11% | الأسهم |
| STATE STREET CORP | $1169252484 | 5516643 | 9,09% | الأسهم |
| GEODE CAPITAL MANAGEMENT, LLC | $584135885 | 2767754 | 4,54% | الأسهم |
| EdgePoint Investment Group Inc. | $476372038 | 2247568 | 3,71% | الأسهم |
| Grantham, Mayo, Van Otterloo & Co. LLC | $400206122 | 1888207 | 3,11% | الأسهم |
| DIMENSIONAL FUND ADVISORS LP | $357050202 | 1684597 | 2,78% | الأسهم |
| Davis Selected Advisers | $329781509 | 1555612 | 2,56% | الأسهم |
| VICTORY CAPITAL MANAGEMENT INC | $311037928 | 1467506 | 2,42% | الأسهم |
| NORGES BANK | $298133109 | 1406620 | 2,32% | الأسهم |
| FMR LLC | $227315614 | 1072496 | 1,77% | الأسهم |
| AMERICAN CENTURY COMPANIES INC | $173422135 | 818220 | 1,35% | الأسهم |
| M&G PLC | $168677800 | 795650 | 1,31% | الأسهم |
| VANGUARD FIDUCIARY TRUST CO | $131756386 | 621639 | 1,02% | الأسهم |
| ALLIANCEBERNSTEIN L.P. | $122662706 | 625894 | 0,95% | الأسهم |
| AMERIPRISE FINANCIAL INC | $109652758 | 517352 | 0,85% | الأسهم |
| Woodline Partners LP | $102974000 | 485841 | 0,80% | الأسهم |
| FIDUCIARY MANAGEMENT INC /WI/ | $102489906 | 483557 | 0,80% | الأسهم |
| Artemis Investment Management LLP | $99175856 | 467921 | 0,77% | الأسهم |
| CRAWFORD INVESTMENT COUNSEL INC | $97514204 | 460081 | 0,76% | الأسهم |
| PRINCIPAL FINANCIAL GROUP INC | $91995201 | 434042 | 0,72% | الأسهم |
| ENVESTNET ASSET MANAGEMENT INC | $90834224 | 428564 | 0,71% | الأسهم |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $86608697 | 407302 | 0,67% | الأسهم |
| BNP PARIBAS FINANCIAL MARKETS | $83772178 | 395245 | 0,65% | الأسهم |
| M.D. Sass, LLC | $76397960 | 360453 | 0,59% | الأسهم |
| Qube Research & Technologies Ltd | $72783206 | 343398 | 0,57% | الأسهم |
| MACKENZIE FINANCIAL CORP | $70641875 | 333295 | 0,55% | الأسهم |
| Advisors Capital Management, LLC | $69429626 | 327575 | 0,54% | الأسهم |
| Swiss National Bank | $65683305 | 309900 | 0,51% | الأسهم |
| Balyasny Asset Management L.P. | $58364883 | 275371 | 0,45% | الأسهم |
| Mitsubishi UFJ Asset Management Co., Ltd. | $56877630 | 268354 | 0,44% | الأسهم |
| RHUMBLINE ADVISERS | $56744612 | 267727 | 0,44% | الأسهم |
| BlackRock, Inc. | $55976419 | 264102 | 0,44% | الأسهم |
| Sumitomo Mitsui Trust Group, Inc. | $54809634 | 258597 | 0,43% | الأسهم |
| VANGUARD ASSET MANAGEMENT, Ltd | $53654295 | 253146 | 0,42% | الأسهم |
| Quantinno Capital Management LP | $53607358 | 252924 | 0,42% | الأسهم |
| RAYMOND JAMES FINANCIAL INC | $53249860 | 251238 | 0,41% | الأسهم |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $52211551 | 246339 | 0,41% | الأسهم |
| VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. | $51484139 | 242907 | 0,40% | الأسهم |
| Clark Capital Management Group, Inc. | $51259362 | 241846 | 0,40% | الأسهم |
| Vanguard Global Advisers, LLC | $51025267 | 240742 | 0,40% | الأسهم |
| Legal & General Group Plc | $50185731 | 236781 | 0,39% | الأسهم |
| FIL Ltd | $49419958 | 233168 | 0,38% | الأسهم |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $49341000 | 232797 | 0,38% | الأسهم |
| Eurizon Capital SGR S.p.A. | $47173414 | 222564 | 0,37% | الأسهم |
| BARCLAYS PLC | $45003978 | 212333 | 0,35% | الأسهم |
| PFA Pension, Forsikringsaktieselskab | $43579660 | 205613 | 0,34% | الأسهم |
| Integral Health Asset Management, LLC | $42390000 | 200000 | 0,33% | الأسهم |
| California Public Employees Retirement System | $41574204 | 196151 | 0,32% | الأسهم |
| CONNING INC. | $39578271 | 186734 | 0,31% | الأسهم |
| SEB Asset Management AB | $38766863 | 182906 | 0,30% | الأسهم |
| BANK OF MONTREAL /CAN/ | $38512587 | 181706 | 0,30% | الأسهم |
| GOLDMAN SACHS GROUP INC | $38322295 | 180808 | 0,30% | الأسهم |
| Boston Partners | $35509632 | 167514 | 0,28% | الأسهم |
| Focus Partners Wealth | $34616947 | 163327 | 0,27% | الأسهم |
| STOREBRAND ASSET MANAGEMENT AS | $34117592 | 160970 | 0,27% | الأسهم |
| COOKSON PEIRCE & CO INC | $32977089 | 155589 | 0,26% | الأسهم |
| UBS Group AG | $32934699 | 155389 | 0,26% | الأسهم |
| BRAUN STACEY ASSOCIATES INC | $32724232 | 154396 | 0,25% | الأسهم |
| Willis Investment Counsel | $32110425 | 151500 | 0,25% | الأسهم |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $31795403 | 162238 | 0,25% | الأسهم |
| LPL Financial LLC | $30325576 | 143079 | 0,24% | الأسهم |
| APG Asset Management N.V. | $27869580 | 150334 | 0,22% | الأسهم |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $26893912 | 126888 | 0,21% | الأسهم |
| &PARTNERS | $26382365 | 124363 | 0,21% | الأسهم |
| JANE STREET GROUP, LLC | $25942680 | 122400 | 0,20% | عقد خيار الشراء |
| BANK OF AMERICA CORP /DE/ | $25492499 | 120276 | 0,20% | الأسهم |
| Candriam S.C.A. | $25459925 | 120238 | 0,20% | الأسهم |
| Squarepoint Ops LLC | $24974280 | 117831 | 0,19% | الأسهم |
| Gotham Asset Management, LLC | $24911119 | 117533 | 0,19% | الأسهم |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $24607896 | 116373 | 0,19% | الأسهم |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $24569456 | 115921 | 0,19% | الأسهم |
| Robeco Institutional Asset Management B.V. | $23854123 | 112546 | 0,19% | الأسهم |
| AEGON ASSET MANAGEMENT UK Plc | $22866862 | 107888 | 0,18% | الأسهم |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | $22670926 | 106964 | 0,18% | الأسهم |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $22530921 | 106303 | 0,18% | الأسهم |
| MERCER GLOBAL ADVISORS INC /ADV | $22106507 | 104301 | 0,17% | الأسهم |
| Moran Wealth Management, LLC | $22053609 | 104051 | 0,17% | الأسهم |
| ABN AMRO Bank N.V. | $21523733 | 101667 | 0,17% | الأسهم |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $21496202 | 123876 | 0,17% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $21322170 | 100600 | 0,17% | عقد خيار الشراء |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $21146252 | 99770 | 0,16% | الأسهم |
| AVIVA PLC | $20378569 | 96148 | 0,16% | الأسهم |
| SCHWARTZ INVESTMENT COUNSEL INC | $20326005 | 95900 | 0,16% | الأسهم |
| Boston Common Asset Management, LLC | $20282767 | 95696 | 0,16% | الأسهم |
| CAPTRUST FINANCIAL ADVISORS | $20146790 | 95054 | 0,16% | الأسهم |
| Midwest Trust Co | $20113207 | 94896 | 0,16% | الأسهم |
| LAZARD ASSET MANAGEMENT LLC | $20035210 | 94528 | 0,16% | الأسهم |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | $19842759 | 93620 | 0,15% | الأسهم |
| BLAIR WILLIAM & CO/IL | $19773115 | 93291 | 0,15% | الأسهم |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $19613005 | 92536 | 0,15% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19160280 | 90400 | 0,15% | عقد خيار البيع |
| CITADEL ADVISORS LLC | $18821160 | 88800 | 0,15% | عقد خيار الشراء |
| WELLINGTON MANAGEMENT GROUP LLP | $17507282 | 82601 | 0,14% | الأسهم |
| Foundry Partners, LLC | $17338432 | 102473 | 0,13% | الأسهم |
| MARSHALL WACE, LLP | $17187874 | 81094 | 0,13% | الأسهم |
| Coho Partners, Ltd. | $16981317 | 89103 | 0,13% | الأسهم |
| Copeland Capital Management, LLC | $16902800 | 79749 | 0,13% | الأسهم |
| CIBC Asset Management Inc | $16674318 | 78671 | 0,13% | الأسهم |
| Mitsubishi UFJ Trust & Banking Corp | $16558594 | 78125 | 0,13% | الأسهم |
المطلعون على الشركة 53 من المطلعين · مسؤولون 26 · مديرون 26
| مطلع | الدور | آخر نشاط | الأسهم المملوكة | مشتريات 12 شهرًا | مبيعات 12 شهرًا | صافي 12 شهرًا |
|---|---|---|---|---|---|---|
| E. J. Davis | CEO and President | 1 يونيو، 2026 S | 132423 | 0 | 5 | $-14656302 |
| Surya N Mohapatra | Chairman, President & CEO | 30 إبريل، 2012 F | 243713 | 0 | 0 | $0 |
| Sam Samad | Executive Vice President & CFO | 22 يوليو، 2026 A | 33478 | 0 | 0 | $0 |
| Mark Guinan | Executive Vice President & CFO | 7 مارس، 2022 F | 98981 | 0 | 0 | $0 |
| Robert Hagemann | SVP & Chief Financial Officer | 5 مارس، 2013 F | 126722 | 0 | 0 | $0 |
| Mark E Delaney | SVP & Chief Commercial Officer | 28 يوليو، 2026 S | 10335 | 0 | 1 | $-376288 |
| Karthik Kuppusamy | SVP, Clinical Solutions | 22 يوليو، 2026 L | 13557 | 0 | 2 | $-2167772 |
| Patrick Plewman | SVP for Diagnostic Services | 22 يوليو، 2026 L | 15293 | 0 | 4 | $-2194322 |
| Catherine T. Doherty | EVP, Regional Businesses | 5 مارس، 2026 S | 67122 | 0 | 7 | $-6671228 |
| Michael E Prevoznik | SVP & General Counsel | 5 مارس، 2026 S | 37557 | 0 | 7 | $-6505199 |
| Michael J Deppe | SVP, Corp. Controller & CAO | 4 مارس، 2026 F | 35196 | 0 | 0 | $0 |
| Mark A Gardner | SVP of Molecular Gen & Oncol | 24 سبتمبر، 2024 F | 4673 | 0 | 0 | $0 |
| Manner Carrie Eglinton | SVP, Advanced Diagnostics | 7 مارس، 2022 F | 48391 | 0 | 0 | $0 |
| Manuel O. Mendez | SVP & Chief Commercial Officer | 17 فبراير، 2021 A | 29045 | 0 | 0 | $0 |
| Robert A Klug | VP, Corporate Controller | 1 مارس، 2019 F | 6261 | 0 | 0 | $0 |
| Jon R Cohen | SVP & Group Exec. Diag. Sol. | 8 مارس، 2018 M | 31757 | 0 | 0 | $0 |
| Everett Cunningham | SVP, Commercial | 1 مارس، 2018 G | 37760 | 0 | 0 | $0 |
| Thomas F Bongiorno | VP and Corporate Controller | 2 مارس، 2015 F | 11837 | 0 | 0 | $0 |
| John B. Haydon | SVP, Operations | 13 فبراير، 2014 A | 19890 | 0 | 0 | $0 |
| Kathy Ordonez | SVP, Diagnostic Solutions | 31 مارس، 2013 F | 9569 | 0 | 0 | $0 |
| Joan Elizabeth Miller | SVP-Oncology & Neurology Srvcs | 29 فبراير، 2012 F | 89232 | 0 | 0 | $0 |
| Wayne R. Simmons | Vice President, Operations | 16 يونيو، 2011 M | 47150 | 0 | 0 | $0 |
| Robert E Peters | VP, Sales & Marketing | 12 فبراير، 2007 A | 12974 | 0 | 0 | $0 |
| David M Zewe | SVP, Diagnostic Testing Ops | 12 فبراير، 2007 A | 31079 | 0 | 0 | $0 |
| GRANT THOMAS W II | Sr VP, Ins. & Employer Serv. | 12 فبراير، 2007 A | — | 0 | 0 | $0 |
| Gerald C Marrone | SVP, Administration | 28 فبراير، 2004 F | 49609 | 0 | 0 | $0 |
| Wright Lassiter III | مدير | 22 يوليو، 2026 L | 10323 | 0 | 0 | $0 |
| Vicky B Gregg | مدير | 22 يوليو، 2026 A | 18386 | 0 | 1 | $-239700 |
| Robert B Carter | مدير | 22 يوليو، 2026 L | 3864 | 0 | 0 | $0 |
| Timothy L Main | مدير | 22 يوليو، 2026 L | 22460 | 0 | 0 | $0 |
| Timothy C Wentworth | مدير | 1 يوليو، 2026 A | 1358 | 0 | 0 | $0 |
| Timothy M Ring | مدير | 20 مايو، 2026 A | 31140 | 0 | 0 | $0 |
| Gary M Pfeiffer | مدير | 20 مايو، 2026 A | 31005 | 0 | 1 | $-270317 |
| Luis Diaz | مدير | 15 مايو، 2025 A | 4054 | 0 | 0 | $0 |
| Tracey Doi | مدير | 15 مايو، 2025 A | 6490 | 0 | 0 | $0 |
| Gail R Wilensky | مدير | 17 مايو، 2023 A | 20506 | 0 | 0 | $0 |
| Stephen H Rusckowski | مدير | 6 مارس، 2023 F | 389597 | 0 | 0 | $0 |
| Helen Torley | مدير | 25 مايو، 2021 A | 6260 | 0 | 0 | $0 |
| Daniel Stanzione | مدير | 23 نوفمبر، 2020 S | 28349 | 0 | 0 | $0 |
| Jenne K Britell | مدير | 4 يونيو، 2018 G | 14479 | 0 | 0 | $0 |
| Jeffrey M Leiden | مدير | 29 مايو، 2018 S | 6000 | 0 | 0 | $0 |
| John B Ziegler | مدير | 22 فبراير، 2017 S | 16557 | 0 | 0 | $0 |
| John C Baldwin MD | مدير | 12 أغسطس، 2015 S | 12949 | 0 | 0 | $0 |
| William F Buehler | مدير | 12 فبراير، 2014 M | 26225 | 0 | 0 | $0 |
| GSK plc | مدير | 31 يناير، 2011 S | 0 | 0 | 0 | $0 |
| Rosanne Haggerty | مدير | 6 مايو، 2010 A | 9334 | 0 | 0 | $0 |
| William R Grant | مدير | 1 إبريل، 2007 A | 3334 | 0 | 0 | $0 |
| James F Flaherty III | مدير | 4 مايو، 2006 A | 1667 | 0 | 0 | $0 |
| Kenneth D Brody | مدير | 28 إبريل، 2004 S | 0 | 0 | 0 | $0 |
| Mary A Cirillo | مدير | 1 إبريل، 2004 A | 2627 | 0 | 0 | $0 |
المطلعون من إيداعات SEC Form 3/4/5؛ صافي = سوق مفتوح فقط
الناشطون والمالكون بنسبة 5%+ 13 حيازة
المستثمرون الذين قدموا الجدول الزمني 13D لدى هيئة الأوراق المالية والبورصات — ملكية مستفيدة تزيد عن 5% مع نية التأثير على المُصدر (حصص الناشطين، حملات مجلس الإدارة، الاندماج والاستحواذ). يعرض كل صف أحدث حالة معروفة لمركز مقدم الطلب هذا.
| مقدم | مقدم | حصة | الحالة | الغرض | إيداع |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated | 18 مايو، 2011 | — | إيداع أولي | اندماج واستحواذ / بيع | SEC |
| شخص مُبلِّغ لم يُكشف عنه | 1 فبراير، 2011 | — | إيداع أولي | استثمار سلبي | SEC |
| شخص مُبلِّغ لم يُكشف عنه | 20 مارس، 2009 | — | إيداع أولي | — | SEC |
| GlaxoSmithKline plc ×2 إيداعات | 18 سبتمبر، 2008 | — | إيداع أولي | — | SEC |
| شخص مُبلِّغ لم يُكشف عنه | 16 فبراير، 2007 | — | إيداع أولي | — | SEC |
| Quest Diagnostics Incorporated - (FEIN No. ×2 إيداعات | 19 يناير، 2006 | — | إيداع أولي | — | SEC |
| شخص مُبلِّغ لم يُكشف عنه | 15 ديسمبر، 2004 | — | إيداع أولي | — | SEC |
| شخص مُبلِّغ لم يُكشف عنه | 29 يونيو، 2004 | — | إيداع أولي | — | SEC |
| شخص مُبلِّغ لم يُكشف عنه | 24 يونيو، 2002 | — | إيداع أولي | اندماج واستحواذ / بيع | SEC |
| شخص مُبلِّغ لم يُكشف عنه | 22 مايو، 2002 | — | إيداع أولي | — | SEC |
| شخص مُبلِّغ لم يُكشف عنه | 12 إبريل، 2002 | — | إيداع أولي | اندماج واستحواذ / بيع | SEC |
| IRS Identification Nos. of Above Persons (entities only) Quest Diagnostics Ventures LLC - (FEIN No., Quest Diagnostics Incorporated - (FEIN No. ×3 إيداعات | 1 نوفمبر، 2001 | — | إيداع أولي | اندماج واستحواذ / بيع | SEC |
| شخص مُبلِّغ لم يُكشف عنه | 14 مايو، 2001 | — | إيداع أولي | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ملكية صناديق المؤشرات المتداولة محتفظ بها بواسطة 185 صناديق مؤشرات متداولة
الوزن يعكس فقط ممتلكات الأسهم المباشرة (N-PORT)؛ قد تحتفظ الصناديق المضاعفة أو القائمة على المشتقات بتعرض إضافي للمقايضة غير معروض.
| صندوق | الوزن | الوحدات | حتى تاريخ | المصدر |
|---|---|---|---|---|
| IHF · iShares Trust | 3,93% | 198579 SH | 20 أغسطس، 2026 | يومي |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,68% | 57951 SH | 20 أغسطس، 2026 | يومي |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,29% | 57932 NS | 30 إبريل، 2026 | N-PORT |
| CZA · Invesco Exchange-Traded Fund Trust | 1,24% | 9488 SH | 20 أغسطس، 2026 | يومي |
| TMFX · RBB Fund, Inc. | 1,05% | 1724 NS | 31 مايو، 2026 | N-PORT |
| ANEW · ProShares Trust | 0,92% | 364 NS | 31 مايو، 2026 | N-PORT |
| QLTY · GMO ETF Trust | 0,85% | 196208 NS | 31 مايو، 2026 | N-PORT |
| ALTL · Pacer Funds Trust | 0,82% | 4047 NS | 30 إبريل، 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,80% | 635 NS | 30 إبريل، 2026 | N-PORT |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,77% | 4426 SH | 20 أغسطس، 2026 | يومي |
| QLV · FlexShares Trust | 0,74% | 6461 NS | 30 إبريل، 2026 | N-PORT |
| GDOC · Goldman Sachs ETF Trust | 0,72% | 741 NS | 31 مايو، 2026 | N-PORT |
| ESMV · iShares Trust | 0,72% | 236 SH | 20 أغسطس، 2026 | يومي |
| HUSV · First Trust Exchange-Traded Fund III | 0,52% | 1956 NS | 30 إبريل، 2026 | N-PORT |
| PRAY · FIS Trust | 0,47% | 1958 NS | 31 مايو، 2026 | N-PORT |
| ITAN · EA Series Trust | 0,46% | 2110 NS | 29 مايو، 2026 | N-PORT |
| BTAL · AGF Investments Trust | 0,46% | 6072 NS | 30 يونيو، 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 0,44% | 1055 NS | 30 إبريل، 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0,44% | 409814 NS | 30 إبريل، 2026 | N-PORT |
| SIXL · EXCHANGE TRADED CONCEPTS TRUST | 0,41% | 3999 NS | 31 مايو، 2026 | N-PORT |
| IYH · iShares Trust | 0,41% | 64443 SH | 20 أغسطس، 2026 | يومي |
| VOE · VANGUARD INDEX FUNDS | 0,40% | 711079 SH | 19 أغسطس، 2026 | يومي |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,38% | 8682 NS | 30 إبريل، 2026 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,37% | 8368 NS | 30 إبريل، 2026 | N-PORT |
| IMCV · iShares Trust | 0,36% | 18030 SH | 20 أغسطس، 2026 | يومي |
| SUSA · iShares Trust | 0,35% | 59963 SH | 20 أغسطس، 2026 | يومي |
| FHLC · FIDELITY COVINGTON TRUST | 0,35% | 51278 NS | 30 إبريل، 2026 | N-PORT |
| FTA · First Trust Exchange-Traded AlphaDE… | 0,34% | 23030 NS | 30 إبريل، 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,34% | 330273 SH | 19 أغسطس، 2026 | يومي |
| IXJ · iShares Trust | 0,32% | 58047 SH | 20 أغسطس، 2026 | يومي |
| RXL · ProShares Trust | 0,31% | 1147 NS | 31 مايو، 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,31% | 2194 NS | 30 إبريل، 2026 | N-PORT |
| GNOM · Global X Funds | 0,28% | 789 NS | 31 مايو، 2026 | N-PORT |
| DFLV · Dimensional ETF Trust | 0,26% | 79983 NS | 30 إبريل، 2026 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,26% | 7703000 | 19 أغسطس، 2026 | يومي |
| IWS · iShares Trust | 0,25% | 166379 SH | 20 أغسطس، 2026 | يومي |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,24% | 18806 NS | 30 إبريل، 2026 | N-PORT |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0,24% | 8995 NS | 30 إبريل، 2026 | N-PORT |
| EQIN · Columbia ETF Trust I | 0,23% | 3340 NS | 30 إبريل، 2026 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0,23% | 26229 NS | 30 إبريل، 2026 | N-PORT |
| SIZE · iShares Trust | 0,23% | 4242 SH | 20 أغسطس، 2026 | يومي |
| DFVE · DoubleLine ETF Trust | 0,23% | 351 NS | 30 يونيو، 2026 | N-PORT |
| VO · VANGUARD INDEX FUNDS | 0,23% | 2398948 SH | 19 أغسطس، 2026 | يومي |
| BFOR · ALPS ETF Trust | 0,22% | 2467 NS | 31 مايو، 2026 | N-PORT |
| EUSA · iShares, Inc. | 0,22% | 18045 SH | 20 أغسطس، 2026 | يومي |
| RSP · Invesco Exchange-Traded Fund Trust | 0,22% | 914353 SH | 20 أغسطس، 2026 | يومي |
| VFMV · VANGUARD WELLINGTON FUND | 0,22% | 4307 SH | 19 أغسطس، 2026 | يومي |
| ACWV · iShares, Inc. | 0,21% | 29381 SH | 20 أغسطس، 2026 | يومي |
| GSEW · Goldman Sachs ETF Trust | 0,20% | 18310 NS | 31 مايو، 2026 | N-PORT |
| DEUS · DBX ETF Trust | 0,20% | 2734 NS | 29 مايو، 2026 | N-PORT |